A Detailed Analysis of Cost-Drivers in Healthcare Expenditures in IBD
Findings presented at the 2024 Crohns’ and Colitis Congress show the significant burden of unmanaged IBD symptoms driving significant ER and high-cost medication utilization Care for inflammatory bowel diseases (IBD) carries a significant financial burden on the US healthcare system and these costs are rapidly increasing.